The sophisticated ion channel modulation by ginsenosides—activating potassium channels while inhibiting calcium and sodium currents—provides a more physiological approach to arrhythmia management compared to traditional single-channel blockers [29–32]. The gene discussed is KCNA3; the disease is cardiac arrhythmia.